Monday, February 10, 2025

Glox Therapeutics Secures £500K Grant to Combat AMR in Cystic Fibrosis

Similar articles

Key Takeaways

  • Glox Therapeutics receives £500,000 from the CF AMR Syndicate’s Collaborative Discovery Programme (CDP) to develop precision antibiotics.
  • Funding targets solutions for antimicrobial-resistant (AMR) lung infections in cystic fibrosis (CF) patients.
  • Cross-sector collaboration will accelerate discovery and enhance patient outcomes.

Glox Therapeutics has been awarded £500,000 as part of the £3M Collaborative Discovery Programme (CDP), launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from LifeArc. The funding will propel the company’s development of novel precision antibiotics targeting antimicrobial-resistant (AMR) lung infections in cystic fibrosis (CF) patients—a growing global health challenge.

Subscribe Weekly Market Access News

* indicates required

With over 162,000 people worldwide living with CF, managing lung infections caused by bacteria like Pseudomonas aeruginosa remains a critical unmet need. Standard antibiotics often fail due to resistance, exacerbating health complications. Glox Therapeutics’ proprietary protein bacteriocin engineering platform offers a groundbreaking solution, selectively eradicating drug-resistant pathogens while preserving the human microbiome.

“This funding is a vital step toward addressing the pressing need for effective therapies to combat AMR in CF patients,” said Dr. James Clark, CEO and Co-Founder of Glox Therapeutics. “With the collaborative support of the CF AMR Syndicate, we’re advancing precision antibiotics to improve the lives of those battling chronic infections.”

Collaborative Efforts to Tackle AMR

The CF AMR Syndicate, a cross-sector initiative led by Medicines Discovery Catapult, LifeArc, and the Cystic Fibrosis Trust, provides Glox Therapeutics access to resources, expertise, and real-world insights. By uniting leaders from academia, industry, and the clinic with patient perspectives, the Syndicate aims to accelerate the development of cutting-edge antimicrobial solutions.

“Collaboration is essential to unlocking breakthroughs in AMR and CF research,” stated Dr. Catherine Kettleborough, Head of Chronic Respiratory Infection Translational Challenge at LifeArc. “We’re proud to support Glox Therapeutics’ pioneering work.”

The Syndicate’s efforts also address the broader public health crisis posed by AMR, which is predicted to result in 10 million deaths annually and cost the global economy $100 trillion by 2050.

Transforming Treatment for CF Lung Infections

Glox Therapeutics’ novel antibiotics harness engineered bacteriocins—naturally occurring proteins with potent, narrow-spectrum activity. These therapies precisely target Gram-negative AMR pathogens, reducing collateral damage to the microbiome. By focusing on precision medicine, the company aims to deliver life-changing treatments for CF and beyond.

“Lung infections disrupt daily life and lead to irreversible lung damage in CF patients,” said Dr. Paula Sommer, Head of Research and Partnerships at the Cystic Fibrosis Trust. “We’re excited to see projects like Glox Therapeutics’ advancing urgently needed antimicrobial solutions.”With the CDP grant, Glox Therapeutics is poised to accelerate preclinical development, positioning its projects for further investment and clinical translation.

Source

You can follow our news on our Telegram, LinkedIn and Youtube accounts.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article